The effect of heterogeneous hyperimmune IgG antibody on prophylaxis and treatment of <i>Pneumocystis carinii</i> infection in rats

, Lee, M; , Cho, S R; , Park, Y K; , Choi, M H; , Hong, S T

doi:1998.36.2.127

Korean J Parasito > Volume 36(2):1998 > Article

Original Article


Korean J Parasitol. 1998 Jun;36(2):127-132. English. Published online Jun 20, 1998. http://dx.doi.org/10.3347/kjp.1998.36.2.127
Copyright © 1998 by The Korean Society for Parasitology


The effect of heterogeneous hyperimmune IgG antibody on prophylaxis and treatment of Pneumocystis carinii infection in rats
M Lee,S R Cho,Y K Park,M H Choi and S T Hong^*
Department of Parasitology, Seoul National University College of Medicine, Korea.

Received March 17, 1998; Accepted April 15, 1998.
Abstract
Immunotherapy has been used in support of trimethoprim-sulfamethoxazole treatment for Pneumocystis carinii pneumonia. The present study investigated the therapeutic or preventive effects of heterogeneous hyperimmune IgG antibody (HIA) in experimental rats. Their immunity was suppressed by steroid injection, and they were also injected peritoneally with HIA which reacted with 40-55, 92, 116, and 200 kDa bands of the crude antigen. All rats were infected by P. carinii and the cystic forms on lung impression smears were counted. The count was 20.5-76.5 (mean 52.5 ± 19.3) in those which received steroid only, but decreased to 6.0-21.0 (mean 13.5 ± 10.6) in those of group 3 which received HIA for the same duration. In other groups, the mean count ranged from 29.9 ± 32.9 to 54.1 ± 47.7, and in those which received 13.7 mg HIA the reduction effect was greater than in those which received 6.8 mg or 20.5 mg HIA. The present finding confirmed that in rats during the early stage of infection, the heterogeneous HIA to MSG antigen bands had a partial effect on P. carinii pneumonia, both prophylactically and therapeutically.

Figures


	Fig. 1 A. SDS-PAGE analysis of crude antigen of rat P. carinii. B. Immunoblot of P. carinii crude antigen to hyperimmune IgG antibody (HIA).


	Fig. 2 Number of P. carinii cystic forms on 20 fields of immersion oil magnification of the rat lung impression smears by group.

Tables


	Table 1 Duration of immunosuppression (IS) and timing and dose of hyperimmune IgG antibody (HIA) by experimental groups^a)


	Table 2 Number fo cystic forms of P. carinii in 20 fields of oil immersion lens magnification by group

References


1.	Blumenfeld W, Mandrell RE, Jarvis GA, Griffiss JM. Localization of host immunoglobulin G to the surface of Pneumocystis carinii. Infect Immun 1990;58(2):456–463.

2.	Furuta T, Ueda K, Fujiwara K, Yamanouchi K. Cellular and humoral immune responses of mice subclinically infected with Pneumocystis carinii. Infect Immun 1985;47(2):544–548.

3.	Gigliotti F, Hughes WT. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988;81(6):1666–1668.

4.	Hong ST, Lee M, Seo M, Choo DH, Moon HR, Lee SH. Immunoblot analysis for serum antibodies to Pneumocystis carinii by age and intensity of infection in rats. Korean J Parasitol 1995;33(3):187–194.

5.	Kovacs JA, Halpern JL, Swan JC, Moss J, Parrillo JE, Masur H. Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol 1988;140(6):2023–2031.

6.	Lundgren B, Lundgren JD, Nielsen T, Mathiesen L, Nielsen JO, Kovacs JA. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis 1992;165(6):1151–1155.

7.	Peglow SL, Smulian AG, Linke MJ, Pogue CL, Nurre S, Crisler J, Phair J, Gold JW, Armstrong D, Walzer PD. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis 1990;161(2):296–306.

8.	Roths JB, Sidman CL. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun 1993;61(5):1641–1649.